Click on the links below to read the full story.
Domainex to Present at a Range of Industry Events in December 2011, including Epigenetics Summit in Munich, including:
6th December 2011 - OBN's BioTuesday - What’s new in Oncology: Upstarts and Updates, London, UK- Dr Eddy Littler to describe Domainex's work on the TBK1/IKKe and lysine methyltransferase drug targets
Domainex has been Shortlisted by One Nucleus for the 2011 Genesis BioPharma Innovation award.
This is to recognise its work on the development of a new cancer drug against the novel kinase targets TBK1/IKKe. The winner will be announced on 1st December and Domainex hopes to make it a second in a row, after winning the award in 2010.
Domainex Ltd., the UK-based drug discovery company focused on speed and innovation, has been awarded a £250,000 grant by the Technology Strategy Board - the UK’s national innovation agency - to help support the development of a new drug for the treatment of several common cancers.
Chemical & Engineering News (External link)
Cambridge Business Media Interview (External link)
7th March 2011
Business Weekly Interview (External link)
7th March 2011
Domainex Ltd, a biotechnology company providing world-class drug discovery services to support both its own and customer research programmes, has announced plans to significantly expand its medicinal chemistry and biology capabilities in 2011.
The expansion will involve relocation to larger laboratories in Cambridge and investment in new technologies that will enhance its current service offering. This will allow Domainex to provide even better support to its growing client base and enable it to expand work on the Company’s own discovery-phase oncology drug pipeline.
7th January 2011
Scientists at St George’s, University of London and the University of Manchester have received an additional Seeding Drug Discovery award of £390,000 from the Wellcome Trust to explore a new class of experimental drugs that block the trigger of allergic reactions before symptoms show.
The first ADI drug being developed by the team – in collaboration with the expert medicinal chemistry partner Domainex – targets house dust mites, globally one of the commonest causes of domestic allergy and a key trigger of asthma attacks.